Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus

被引:28
|
作者
Kuranov, S. O. [1 ]
Tsypysheva, I. P. [2 ]
Khvostov, M., V [1 ,5 ]
Zainullina, Liana F. [3 ,4 ]
Borisevich, S. S. [2 ]
Vakhitova, Yu V. [3 ,4 ]
Luzina, O. A. [1 ]
Salakhutdinov, N. F. [1 ,5 ]
机构
[1] Russian Acad Sci, Siberian Branch, NN Vorozhtsov Novosibirsk Inst Organ Chem, Novosibirsk 630090, Russia
[2] Russian Acad Sci, Ufa Inst Chem, Ufa 450054, Russia
[3] FSBI Zalcusov Inst Pharmacol, Moscow 125315, Russia
[4] IBG UFRC RAS, Ufa 450054, Russia
[5] Novosibirsk State Univ, Novosibirsk 630090, Russia
关键词
DIPEPTIDYL-PEPTIDASE-IV; COMPLICATIONS; EPIDEMIOLOGY; DERIVATIVES; INSULIN; DESIGN; POTENT; DRUGS;
D O I
10.1016/j.bmc.2018.07.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study, bornyl- and cytisine-based cyanopyrrolidines as potent dipeptidyl peptidase-IV (DPP-IV) inhibitors were synthesised. The in vitro inhibiting activities of bornyl- and cytisine derivatives towards DPP-IV were evaluated. Bornyl-based cyanopyrrolidines were shown to have moderate inhibitory activity with regard to DPP-IV (1.27-15.78 mu M). A docking study was performed to elucidate the structure-activity relationship of the obtained compounds. The in vivo hypoglycemic activities of the same compounds were evaluated with the oral glucose tolerance test (OGTT) in mice. Bornyl-based cyanopyrrolidines were shown to have good hypoglycemic activity.
引用
收藏
页码:4402 / 4409
页数:8
相关论文
共 50 条
  • [1] Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes
    Nielsen, LL
    DRUG DISCOVERY TODAY, 2005, 10 (10) : 703 - 710
  • [2] DPP-IV inhibitors (1): Synthesis and evaluation of 3-or 4-substituted 2-cyanopyrrolidines.
    Fukushima, H
    Hiratate, A
    Takahashi, M
    Kitano, K
    Yamamoto, K
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U16 - U16
  • [3] Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors
    Salvatore, Teresa
    Carbonara, Ornella
    Cozzolino, Domenico
    Torella, Roberto
    Sasso, Ferdinando C.
    CURRENT DIABETES REVIEWS, 2009, 5 (02) : 92 - 101
  • [4] Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of Type 2 diabetes
    Benbow, John W.
    Andrews, Kim A.
    Aubrecht, Jiri
    Beebe, David
    Boyer, David
    Doran, Shawn
    Homiski, Michael
    Hui, Yu
    McPherson, Kirk
    Parker, Janice C.
    Treadway, Judith
    VanVolkenberg, Maria
    Zembrowski, William J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (08) : 2220 - 2223
  • [5] Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors
    Holst, JJ
    DIPEPTIDYL AMINOPEPTIDASES IN HEALTH AND DISEASE, 2003, 524 : 263 - 279
  • [6] Management of Type 2 Diabetes Mellitus by DPP-IV Inhibition - A Review
    Divya, K.
    Vivek, H. K.
    Prasad, Nagendra M. N.
    Priya, B. S.
    Swamy, Nanjunda S.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND PHYTOPHARMACOLOGICAL RESEARCH, 2014, 4 (02): : 138 - 143
  • [7] Incretin mimetics and DPP-IV inhibitors: New paradigms for the treatment of type 2 diabetes
    Hinnen, Deborah
    Nielsen, Loretta L.
    Waninger, Amy
    Kushner, Pamela
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2006, 19 (06) : 612 - 620
  • [8] N-substitututed glycyl 2-cyanopyrrolidines as a new family of DPP-IV inhibitors and their potential use in type 2 diabetes.
    Villhauer, EB
    Anderson, RC
    Balkan, B
    Barilla, D
    Brinkman, JA
    Dunn, E
    Dunning, B
    Graham, ED
    Gu, HPH
    Gutierrez, CM
    Hamilton, BH
    Kwasnik, LA
    Li, X
    Mangold, BL
    Maniara, WM
    Miserendino-Molteni, R
    Mone, M
    Nader, GB
    Ramos, KL
    Russell, ME
    Rothenberg, PL
    Tullman, RH
    Valentin, M
    Walter, RE
    Weldon, SC
    Hughes, TE
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U60 - U60
  • [9] Natural drug leads as novel DPP-IV inhibitors targeting the management of type 2 diabetes mellitus
    Wasana, Keddagoda Gamage Piyumi
    Attanayake, Anoja Priyadarshani
    Jayatilaka, Kamani Ayoma Perera Wijewardana
    Weerarathna, Thilak Priyantha
    JOURNAL OF COMPLEMENTARY MEDICINE RESEARCH, 2020, 11 (01): : 43 - 53
  • [10] Dipeptidyl peptidase IV (DPP-IV) inhibition as a treatment for Type 2 diabetes
    Thornberry, NA
    FASEB JOURNAL, 2005, 19 (05): : A1723 - A1723